MNMD: Mind Medicine Company Short-Term Debt

Symbol and logo of brand Mind Medicine (MindMed) Inc. (MNMD)

This price trend chart for Mind Medicine (MNMD) reflects the dynamics of a biotech developer whose success depends on the advancement of the MM120 anxiety drug following FDA approval. The current indicator is 0.00. Mind Medicine (MNMD) is implementing automated bioanalysis systems to accelerate the testing of new compounds. The business foundation relies on proprietary patents in neuropharmacology and the creation of advanced therapies for psychiatric disorders.

MNMD (Mind Medicine (MindMed) Inc.) Company Short-Term Debts history from 07/04/2022 to 01/15/2026

Comprehensive metric breakdowns and analytics for Mind Medicine Corp (MNMD)

- current quotes and average value forecast:
Price Chart MindMed|MNMD - Fair Value Consensus
- market capitalization information:
Market Value Mind Medicine (MindMed) Inc.|MNMD - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share MindMed|MNMD - Book Capitalization|Market Cap to Net Assets Ratio mindmed.co|MNMD - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Mind Medicine|MNMD - Long-Term Liabilities to Equity|Short-Term Debt to Equity Mind Medicine|MNMD - Company Total Debt Obligations|Debt to Book Value Mind Medicine (MindMed) Inc.|MNMD - Long-Term Debt|Company Short-Term Debts MindMed|Quick Ratio mindmed.co
- net income and valuation multiples indicators:
MNMD - Final Profit
Fundamental company analysis:MindMed - MNMD
Mass-produced product of Mind Medicine

Mind Medicine develops innovative psychedelic therapies, which requires significant capital in the absence of current sales. By analyzing the company's short-term loans and credits, an investor sees the aggregate of all liabilities maturing within one year. This metric measures liquidity and the risk of cash flow gaps. This chart reflects the efficiency of working capital management amid high R&D expenses. An increase in the debt load may signal financial instability until the point of market monopolization.

Main competitors

ALKS - Company Short-Term Debt|Company Short-Term Loans and Borrowings AVDL (Avadel Pharmaceuticals PLC)|atai Life Sciences Corp (ATAI) - Company Short-Term Debt|Company Current Liabilities GH Research Group|CMPS (COMPASS Pathways plc) - Company Short-Term Debts|Company Short-Term Debts lbpharma.us|Company Current Liabilities DRUG (Bright Minds Biosciences Inc.)|VNDA (Vanda Pharma) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Cybin CYBN|ANRO (Alto Neuroscience Corp) - Current Liabilities|NRXP - Company Short-Term Debt|Short-Term Debt Volume Cingulate Inc. CING|SILO (Silo Pharma) - Company Current Liabilities|Short-Term Debt China Pharma Holdings, Inc. (CPHI)|CMND (Clearmind Medicine Inc.) - Company Short-Term Debts|Company Current Liabilities Psyence Bio (PBM)|Company Short-Term Debts SPRC|SEEL (seelostherapeutics.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Virpax Pharmaceuticals, Inc. VRPX|Karuna Therapeutics Inc (KRTX) - Short-Term Debt